Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold 2,055 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On February 19, 2025, William L. Macias, the Chief Medical Officer of Immunovant, Inc., sold 2,055 shares of Immunovant's common stock.
• The shares were sold at a weighted average price of $20.86 per share, with individual transactions ranging from $20.51 to $21.09.
• This sale was to cover tax withholding obligations associated with the vesting of 7,051 restricted stock units (RSUs) on February 17, 2025, which were part of a grant of 112,816 RSUs on August 17, 2022.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction and was not a discretionary transaction by Mr. Macias.
• Following the transaction, Mr. Macias still beneficially owns 357,353 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock transaction for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.

Industry Context

This Form 4 filing is a routine disclosure related to insider stock transactions and is a common occurrence for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• The 'sell to cover' practice for tax obligations is a standard method used by companies to manage the tax implications of RSU vesting for their employees.
• Form 4 filings are a standard regulatory requirement for reporting insider transactions, ensuring transparency and preventing insider trading.

Stakeholder Impact

• The sale of shares by an executive could have a minor, short-term impact on shareholder sentiment, but is unlikely to have a significant long-term effect.
• The 'sell to cover' policy impacts employees by providing a mechanism to manage tax obligations related to equity compensation.

Key Dates